GEMPHARMATECH released its performance for the first three quarters, with a net profit attributable to the parent company of 110 million yuan, a year-on-year increase of 11.9%

According to the Zhitong Finance APP, GEMPHARMATECH disclosed its third-quarter report for 2025. The company achieved revenue of 576 million yuan in the first three quarters, a year-on-year increase of 12.92%; the net profit attributable to shareholders of the listed company was 110 million yuan, a year-on-year increase of 11.9%; the net profit excluding non-recurring gains and losses was 92.79 million yuan, a year-on-year increase of 29.21%; the basic earnings per share were 0.27 yuan

GEMPHARMATECH: Net profit in the first half of 2025 was 70.9055 million yuan, a year-on-year decrease of 7.12%

In the first half of 2025, GEMPHARMATECH's operating revenue was 375 million yuan, a year-on-year increase of 10.11%; net profit was 70.9055 million yuan, a year-on-year decrease of 7.12%. The company plans to distribute a cash dividend of 0.3 yuan for every 10 shares based on the total share capital registered on the equity distribution registration date, totaling 12.2697 million yuan, accounting for 17.30% of the net profit

The CRO sector rose, with JOINN up 8.94%, GEMPHARMATECH up 7.3%, Bide up 6.7%, and TIGERMED, Chemexpress, and Sun-Novo all rising over 5%

Overview of the lifting of restrictions on A-shares by Zhitong | April 25

On April 25th, a total of 5 listed companies had their restricted shares unlocked, with a total market value of approximately 5.599 billion yuan. The specific situation of the restricted share unlock today is as follows: Stock Abbreviation Stock Code Restricted Share Type Unlock Shares Guody Technology 002694 Additional A Shares Legal Person Allocation Listed 166 million Jiecang Linear Motion Technology 603583 Equity Incentive Restricted Circulation 237,500 FLARIANT 605566 Extended Restricted Lock-up Period Circulation 71.052 million Kaierda 688255 39.97563 million GEMPHARMATECH 688046 6.206 billion

GemPharmatech opens new biotech hub in San Diego, boosting research capabilities with lab and vivarium.

A state-of-the-art laboratory and rodent vivarium facility has been established in North America to bolster preclinical research capabilities. GemPharmatech, a prominent provider of genetically engineered mouse models and preclinical contract research services, unveiled this facility in San Diego on April 17, 2025. The facility aims to enhance research infrastructure and support innovative studies in the region.